Congratulations to HEPTA Medical, a Sofinnova Partners MD Start portfolio company, on the first close of its Series A round. HEPTA Medical is a pioneering company dedicated to providing an efficient, safe, and minimally-invasive thermal ablation therapy for early-stage lung cancer. The recently raised capital will be used to support the regulatory approval process for the first version of HEPTA Medical’s microwave ablation platform and to initiate its clinical validation. Learn more: https://t.ly/lH-0L Cécile Dupont Redon, Thomas Bancel, Gerard Hascoët #medtech #lungcancer #SeriesA
Sofinnova Partners’ Post
More Relevant Posts
-
🌟 We’re excited to connect at #ESMO24! Share your upcoming projects with Bluprint Oncology and learn how we can add fuel to your success. DM us to set a meeting with our team during ESMO next week! #oncology #pharma #biotech #innovation #cancerresearch #medcomms #ESMO #scientificstrategy
#ESMO24: In just ONE WEEK, the ESMO Congress 2024 begins! 🗓️ Get ready for groundbreaking research, cutting-edge advancements, and inspiring discussions on the future of cancer care. Stay tuned for updates, insights, and highlights from this global gathering of experts! Let’s come together to shape the future of oncology. 🧬 🔗 There is still time to register for ESMO24: https://ow.ly/j4le50Tgkcg
-
-
OncoInfluencers to Follow on Social Media: Dr. Chris Boshoff, MD, PhD, FMedSci https://lnkd.in/dqzzsmjm #Cancer #CancerBiology #CancerResearch #OncoDaily #OncoInfluencers #Oncology #Pfizer #Research
-
-
Chief Medical Officer at CLEARA Biotech BV, leading clinical development, translational science and medical affairs in oncology projects
Novel and exciting data from Cleara Biotech B.V.'s research portfolio were presented yesterday by Diana Putavet at the AM poster session of the American Association for Cancer Research 2024 meeting in San Diego. The presentation summarized the effect of a proprietary peptide that profoundly disrupts FOXO4-p53 binding in preclinical models of triple-negative breast cancer (TNBC). The agent's highly innovative MOA pertains to siphoning peptide-bound p53 thus inducing apoptosis. The effect is specific to cancer cells that have undergone 'scarring' post-cell stress. These cells are highly malignant, resistant to standard therapies, and hyperproliferative, despite their SASP phenotype. Metastatic lesions in both humans and rodents are highly enriched in scarred cells, across assorted histologies, with key tumor types - among others- being TNBC, high-grade serous ovarian Ca and GI malignancies. Of note, the potent proapoptotic effects of CLEARA's peptides on the growth of scarred cancer cells in various preclinical models (both in vitro and in vivo) are independent of the transcriptional activity status of the p53 target, or the presence vs absence of p53 mutations. Our international cross-functional team, led by Peter de Keizer in Utrecht, NL is poised to complete the set of fundamental preclinical experiments on CLEARA's flagship asset, CL04183, within the year. I am excited and honored to be leading the plans for entry of this very promising potentially best-in-class agent in the clinics, supported by an enlarging network of clinical and translational scientific leaders both in the EU and US. For more information on CLEARA, please visit: www.clearabiotech.com. #apoptosis #tp53 #foxo4 #cancer #tnbc #breastcancer #clinicaltrials #IND #CTA #celldeath #cancercell #cellbiology #oncology #cancerresearch #translationalmedicine #mutation #metastasis #resistance #targetedtherapy #chemotherapy #xrt #radiotherapy #aacr24
With a background in cancer research, working on drug development within a utrecht-based biotech startup
Had a great time yesterday at AACR, where I shared my research on breast cancer and had insightful discussions with fellow attendees. This work wouldn't have been possible without the invaluable contributions of Marjolein Baar, Esmée Bouma, Johannes Lehmann, and Peter de Keizer. #research #networking #clearabiotech #umcutrecht
-
-
⏰ Just ONE DAY until our highly-anticipated webinar on bivalent degraders! Mark your calendars and join Katie and Thomas to explore the latest trends, emerging targets, and potential applications in cancer and non-cancer indications.👇 https://lnkd.in/e_gzbUpg Here's what you can expect: 🔬 Analysing novel bivalent degrader effectors (Top 5 Cancer and Non-Cancer) 📈 Addressing the commercial growth within the bivalent landscape 💊 Deep dive into the Preclinical and Clinical data success stories 🔍 Live Q&A, have your questions answered! #TPD #BivalentDegraders #PROTACS
-
-
ESMO 2024 Quick Takes with LARVOL: Guru Sonpavde, MD In this post-ESMO 2024 Quick Take, Dr. Guru Sonpavde, MD, shares his insights on the practice-changing NIAGARA trial. This randomized phase 3 study, involving approximately 1,000 patients, evaluated neoadjuvant gemcitabine, cisplatin, with or without durvalumab for muscle-invasive bladder cancer. The results showed significant improvements in both event-free survival (hazard ratio: 0.68) and overall survival (hazard ratio: 0.75), signaling a major shift in treatment approaches. Stay tuned for more post-ESMO reflections and updates on how this trial may shape future clinical practice. #ESMO24 #CancerResearch #NIAGARATrial #LARVOLQuickTake
-
How is Amgen tackling cancer’s toughest challenges? Live from #ASCO24, oncology leaders Brian Heath, Jean-Charles Soria, MD, PhD, and Sumita Bhatta discuss how we are advancing care for patients with complex and highly aggressive forms of cancer. ➡️ Visit us at booth #30073 to learn more about Amgen innovation.
-
Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024. URL - https://bit.ly/3Kpwz7c
Therapeutic Area Lead Oncology bei Charles River Discovery Research Services Germany GmbH
Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024. URL - https://bit.ly/3Kpwz7c
-
-
Therapeutic Area Lead Oncology bei Charles River Discovery Research Services Germany GmbH
Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024. URL - https://bit.ly/3Kpwz7c
-
-
Did you miss the 2024 ASCO Annual Meeting? Our analysts at Biomedtracker have you covered! Download our comprehensive post-event report recapping key presentations, announcements, and advances shared. https://ow.ly/EmXB50SUJR0 Stay up-to-date with the latest trends and breakthroughs in oncology research. Download the report today and share with your colleagues. #ASCO2024 #Oncology #Biomedtracker #ASCOHighlights #OncologyInsights #BiomedAnalysis
-
-
ICYMI: This course presented at the 2023 ARRS Annual Meeting offers a collection of focused talks detailing approaches to pancreatic cancer staging, pancreatic cysts, and dual energy applications. https://lnkd.in/ejf7KskP
-
👏 Congrats to HEPTA Medical and Sofinnova Partners! 👏 With €5.7M raised, HEPTA’s microwave ablation platform is set to transform early-stage lung cancer treatment. Research backs the effectiveness of this minimally invasive tech (Han et al., 2019), and HEPTA’s AI-driven innovation will only enhance precision and safety.